BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bullard BL, Weaver EA. Strategies Targeting Hemagglutinin as a Universal Influenza Vaccine. Vaccines (Basel) 2021;9:257. [PMID: 33805749 DOI: 10.3390/vaccines9030257] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Sekiya T, Ohno M, Nomura N, Handabile C, Shingai M, Jackson DC, Brown LE, Kida H. Selecting and Using the Appropriate Influenza Vaccine for Each Individual. Viruses 2021;13:971. [PMID: 34073843 DOI: 10.3390/v13060971] [Reference Citation Analysis]
2 Dong C, Wang B. Engineered Nanoparticulate Vaccines to Combat Recurring and Pandemic Influenza Threats. Advanced NanoBiomed Research 2022;2:2100122. [DOI: 10.1002/anbr.202100122] [Reference Citation Analysis]
3 Chen J, Wang J, Zhang J, Ly H. Advances in Development and Application of Influenza Vaccines. Front Immunol 2021;12:711997. [PMID: 34326849 DOI: 10.3389/fimmu.2021.711997] [Reference Citation Analysis]
4 Mittal N, Sengupta N, Malladi SK, Reddy P, Bhat M, Rajmani RS, Sedeyn K, Saelens X, Dutta S, Varadarajan R. Protective Efficacy of Recombinant Influenza Hemagglutinin Ectodomain Fusions. Viruses 2021;13:1710. [PMID: 34578291 DOI: 10.3390/v13091710] [Reference Citation Analysis]
5 Scala MC, Agamennone M, Pietrantoni A, Di Sarno V, Bertamino A, Superti F, Campiglia P, Sala M. Discovery of a Novel Tetrapeptide against Influenza A Virus: Rational Design, Synthesis, Bioactivity Evaluation and Computational Studies. Pharmaceuticals (Basel) 2021;14:959. [PMID: 34681184 DOI: 10.3390/ph14100959] [Reference Citation Analysis]
6 Keresztes G, Baer M, Alfenito MR, Verwoerd TC, Kovalchuk A, Wiebe MG, Andersen TK, Saloheimo M, Tchelet R, Kensinger R, Grødeland G, Emalfarb M. The Highly Productive Thermothelomyces heterothallica C1 Expression System as a Host for Rapid Development of Influenza Vaccines. Vaccines 2022;10:148. [DOI: 10.3390/vaccines10020148] [Reference Citation Analysis]
7 Creytens S, Pascha MN, Ballegeer M, Saelens X, de Haan CAM. Influenza Neuraminidase Characteristics and Potential as a Vaccine Target. Front Immunol 2021;12:786617. [PMID: 34868073 DOI: 10.3389/fimmu.2021.786617] [Reference Citation Analysis]
8 Carascal MB, Pavon RDN, Rivera WL. Recent Progress in Recombinant Influenza Vaccine Development Toward Heterosubtypic Immune Response. Front Immunol 2022;13:878943. [PMID: 35663997 DOI: 10.3389/fimmu.2022.878943] [Reference Citation Analysis]
9 Ravikumar R, Chan J, Prabakaran M. Vaccines against Major Poultry Viral Diseases: Strategies to Improve the Breadth and Protective Efficacy. Viruses 2022;14:1195. [DOI: 10.3390/v14061195] [Reference Citation Analysis]
10 Isakova-Sivak I, Stepanova E, Mezhenskaya D, Matyushenko V, Prokopenko P, Sychev I, Wong PF, Rudenko L. Influenza vaccine: progress in a vaccine that elicits a broad immune response. Expert Rev Vaccines 2021;:1-16. [PMID: 34348561 DOI: 10.1080/14760584.2021.1964961] [Reference Citation Analysis]